Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Polarized Light Therapy for Radiation Dermatitis in Breast Cancer

NCT: NCT07600957 · RECRUITING

NCT IDNCT07600957
StatusRECRUITING
Start Date2026-05-21
Completion2027-01-31

Brief Summary

This assessor-blinded randomized controlled trial aims to evaluate the efficacy of polarized polychromatic non-coherent light therapy as an adjunct to standard skin care in reducing acute radiation dermatitis in women with breast cancer undergoing hypofractionated whole-breast radiotherapy. Participants will be randomly allocated to receive either standard skin care alone or standard care combined with polarized light therapy initiated from the first radiotherapy session. Outcomes will include objective ultrasound-based dermal thickness measurements, clinical severity of radiation dermatitis using Radiation Therapy Oncology Group (RTOG) criteria.

Frequently Asked Questions

What is Polarized Light Therapy for Radiation Dermatitis in Breast Cancer?

Polarized Light Therapy for Radiation Dermatitis in Breast Cancer is a clinical trial registered under NCT07600957. Current status: RECRUITING.

What is the status of NCT07600957?

The current status of NCT07600957 (Polarized Light Therapy for Radiation Dermatitis in Breast Cancer) is: RECRUITING.

When did Polarized Light Therapy for Radiation Dermatitis in Breast Cancer start?

Polarized Light Therapy for Radiation Dermatitis in Breast Cancer started on 2026-05-21.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.